Skip to main content
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. — Investor Relations & Filings

Ticker · ANRO ISIN · US02157Q1094 US Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2026-05-28 Board/Management Inform…
Country US United States of America
Listing US ANRO

About Alto Neuroscience, Inc.

https://www.altoneuroscience.com/

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric conditions. The company's approach utilizes its Precision Psychiatry Platform, which leverages neurobiological data such as EEG and cognitive assessments to identify patient subpopulations most likely to respond to its targeted drug candidates. This biology-driven method aims to move beyond the traditional trial-and-error approach in mental health treatment by predicting clinical response. Alto's clinical-stage pipeline includes novel drug candidates designed to address core brain processes in conditions such as major depressive disorder, bipolar depression, and schizophrenia.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 90% confidence The document is a Form 8-K current report under Item 5.02 announcing the appointment of a new board director and related governance and compensation details. This clearly fits the category of a board/management change announcement.
2026-05-28 English
10-Q - Alto Neuroscience, Inc. (0001999480) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Alto Neuroscience, Inc. (0001999480) (Filer)
Earnings Release Classification · 92% confidence The document is a Form 8-K filed by Alto Neuroscience on May 13, 2026, with Item 2.02 ‘Results of Operations and Financial Condition,’ furnishing a press release of financial results for the quarter ended March 31, 2026. This is the initial public announcement of quarterly results, matching the definition of an Earnings Release. Therefore, it should be classified as ER. Q1 2026
2026-05-13 English
S-3 - Alto Neuroscience, Inc. (0001999480) (Filer)
Regulatory Filings
2026-04-10 English
8-K - Alto Neuroscience, Inc. (0001999480) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about topline data from a Phase 2 study and pipeline advancements, attached as an exhibit. The document is short (3805 characters) and primarily serves as an announcement of an event and press release rather than a detailed financial report or earnings release. It does not contain comprehensive financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-01 English
4 - ALTO NEUROSCIENCE, INC. (0001999480) (Filer)
Director's Dealing
2026-03-04 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.